A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company We are a metabolic therapeutics company focused on breaking the pattern of treatment of metabolic diseases, including obesity and type 2 diabetes (“T2D”). Despite advances in treatment over the last 50 years, obesity and T2D continue to be principal and rapidly growing drivers of morbidity and mortality. According to the Centers for Disease Control and the International Diabetes Federation, approximately 100 million people in the United States have prediabetes and/or are living with obesity, and an additional 25 million people have T2D and are on medical therapy. Within the past two years, the unmet need in obesity has shifted rapidly from identifying treatments that can achieve short-term weight loss to identifying treatments that can enable durable weight maintenance.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | - |
| Net Income | -70M | -70M | -94M |
| EPS | $-1.62 | $-1.62 | $-45.29 |
| Free Cash Flow | -67M | -67M | -43M |
| ROIC | -260.0% | -68.4% | -52.7% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 1.06 | -0.17 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -94M | -94M | -51M |
| Operating Margin | 0.0% | - | - |
| ROE | -247.8% | -247.8% | - |
| Shares Outstanding | 43M | 43M | 49M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -51M | -94M | -94M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -94M | -70M | -70M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -52.7% | -68.4% | N/M |
| ROE | N/A | -247.8% | -247.8% |
| ROA | -123.7% | -76.4% | -65.2% |
| Cash Flow | |||
| Op. Cash Flow | -43M | -66M | -66M |
| Free Cash Flow | -43M | -67M | -67M |
| Owner Earnings | -47M | -81M | -81M |
| CapEx | 359K | 1.8M | 1.8M |
| Maint. CapEx | 286K | 677K | 677K |
| Growth CapEx | 73K | 1.1M | 1.1M |
| D&A | 286K | 677K | 677K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.3M | 14M | 14M |
| Debt Repayment | 400K | 0 | 0 |
| Balance Sheet | |||
| Net Debt | 22M | -37M | 0 |
| Cash & Equiv. | N/A | N/A | N/A |
| Long-Term Debt | 55M | 30M | 30M |
| Debt/Equity | -0.17 | 1.06 | 0.00 |
| Interest Coverage | -66.7 | -29.9 | -29.9 |
| Equity | -325M | 28M | 28M |
| Total Assets | 76M | 108M | 108M |
| Total Liabilities | 401M | 80M | 80M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -347M | -415M | -415M |
| Working Capital | 24M | 52M | 52M |
| Current Assets | 36M | 72M | 72M |
| Current Liabilities | 11M | 20M | 20M |
| Per Share Data | |||
| EPS | -45.29 | -1.62 | -1.62 |
| Owner EPS | -0.97 | -1.85 | -1.85 |
| Book Value | -6.64 | 0.65 | 0.65 |
| Cash Flow/Share | -0.88 | -1.51 | -1.60 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 48.9M | 43.5M | 43.5M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -0.3 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 3.0 | 0.7 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | -78.6% | -315.8% |
| Market Cap | N/A | 86M | 21M |
| Avg. Price | N/A | 4.77 | 0.49 |
| Year-End Price | N/A | 1.97 | 0.49 |
FRACTYL HEALTH, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
FRACTYL HEALTH, INC. (GUTS) has a 5-year average return on invested capital (ROIC) of -60.5%. This is below average and may indicate limited pricing power.
FRACTYL HEALTH, INC. (GUTS) has a market capitalization of $21M. It is classified as a small-cap stock.
FRACTYL HEALTH, INC. (GUTS) does not currently pay a regular dividend.
FRACTYL HEALTH, INC. (GUTS) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
FRACTYL HEALTH, INC. (GUTS) generated $-67 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
FRACTYL HEALTH, INC. (GUTS) has a debt-to-equity ratio of 1.06. This indicates moderate leverage.
FRACTYL HEALTH, INC. (GUTS) reported earnings per share (EPS) of $-1.62 in its most recent fiscal year.
FRACTYL HEALTH, INC. (GUTS) has a return on equity (ROE) of -247.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for FRACTYL HEALTH, INC. (GUTS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
FRACTYL HEALTH, INC. (GUTS) has a book value per share of $0.65, based on its most recent annual SEC filing.